BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:S-1 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of S-1\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06510010-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:S-1: Phase 2 readout est. (NCT06510010)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Perioperative Oxaliplat
 in With S-1 Combined H. Pylori Eradication in the Management of Locally Ad
 vanced Gastric Cancer\nEstimated primary completion: 28 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06510010
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06490107-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:S-1: Phase 2 readout est. (NCT06490107)
DESCRIPTION:S-1\, phase 2.\nStudy: Durvalumab Combined With S-1 as Adjuvant
  Therapy of Resectable BTC\nEstimated primary completion: 30 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06490107
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664021-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:S-1: Phase 2 readout est. (NCT06664021)
DESCRIPTION:S-1\, phase 2.\nStudy: Exploring the Efficacy and Safety of Tis
 lelizumab in Combination With S-1 in the Treatment of Patients With Postop
 erative Recurrent High-risk Intrahepatic Cholangiocarcinoma\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06664021
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238167-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06238167)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab Plus Chemo
 therapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/G
 EJC\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06238167
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187597-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06187597)
DESCRIPTION:S-1\, phase 2.\nStudy: Consolidation of Toripalimab After Chemo
 radiotherapy in Elderly Esophageal Cancer (EC-CRT-007)\nEstimated primary 
 completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06187597
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555471-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06555471)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Single-arm\, Phase II
  Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in 
 Elderly Patients With Locally Advanced Gastric Cancer\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06555471
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304258-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT07304258)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Prospective\, Phase I
 I Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion T
 herapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytolog
 y Alone or PCI Score ≤10\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07304258
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730373-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT06730373)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: First-line Treatment Wi
 th RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06730373
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867392-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 2 readout est. (NCT07867392)
DESCRIPTION:S-1\, phase 2.\nStudy: Neoadjuvant Iparomlimab and Tuvonralimab
  With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07867392
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813015-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 3 readout est. (NCT05813015)
DESCRIPTION:S-1\, phase 3.\nStudy: Study of Comparing of With and Without S
 equential Therapy of S-1\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05813015
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519591-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:S-1: Phase 2 readout est. (NCT06519591)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Systemic Application of
  Cadonilimab\, LM-302\, and S-1 Combined With Intraperitoneal Infusion of 
 Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With 
 Peritoneal Metastasis\nEstimated primary completion: January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06519591
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070479-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:S-1: Phase 2 readout est. (NCT07070479)
DESCRIPTION:S-1\, phase 2.\nStudy: Combination Therapy for PD-1 Resistant R
 ecurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase
  II Trial\nEstimated primary completion: 30 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07070479
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687357-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:S-1: Phase 2 readout est. (NCT05687357)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab in Combina
 tion With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocar
 cinoma\nEstimated primary completion: 28 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05687357
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383078-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:S-1: Phase 2 readout est. (NCT06383078)
DESCRIPTION:S-1\, phase 2.\nStudy: HR070803 in Combination With Oxaliplatin
 \, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06383078
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356466-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:S-1: Phase 1 readout est. (NCT07356466)
DESCRIPTION:S-1\, phase 1.\nStudy: Clinical Efficacy of Pucotenlimab Combin
 ed With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative
  Advanced Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated p
 rimary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07356466
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385873-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:S-1: Phase 2 readout est. (NCT06385873)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: RC48 Combined With Adeb
 relimab\, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gast
 ric Cancer\nEstimated primary completion: 1 May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06385873
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06213519-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:S-1: Phase 2 readout est. (NCT06213519)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: HIPEC Combined With SOX
  and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritonea
 l Metastasis\nEstimated primary completion: 30 May 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06213519
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727993-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:S-1: Phase 1/2 readout est. (NCT07727993)
DESCRIPTION:S-1\, phase 1/2.\nStudy: Neoadjuvant Propranolol Plus SOX and T
 oripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma\nEstimated prim
 ary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07727993
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05184803-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:S-1: Phase 2 readout est. (NCT05184803)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Phase 2 Study of Neoa
 djuvant Docetaxel\, Oxaliplatin\, S-1 in Patients With Unresectable Locall
 y Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05184803
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025889-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:S-1: Phase 1/2 readout est. (NCT07025889)
DESCRIPTION:S-1\, phase 1/2\, Gastric Cancer.\nStudy: IBI343 Combined With 
 Sintilimab Plus Chemotherapy in Gastric Cancer\nEstimated primary completi
 on: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070258
 89
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06779318-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:S-1: Phase 4 readout est. (NCT06779318)
DESCRIPTION:S-1\, phase 4.\nStudy: Maintenance Chemotherapy With S-1 vs. Ob
 servation After Adjuvant Therapy for Resected Pancreatic Cancer With High 
 Risk of Recurrence/Metastasis\nEstimated primary completion: July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06779318
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04997837-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:S-1: Phase 3 readout est. (NCT04997837)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Study of Adjuvant Chemo
 therapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected 
 pN3 Gastric (G) or GEJ Adenocarcinoma\nEstimated primary completion: 21 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04997837
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733050-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:S-1: Phase 2 readout est. (NCT07733050)
DESCRIPTION:S-1\, phase 2.\nStudy: Efficacy and Safety of Serplulimab in Co
 mbination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Ther
 apy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\nEstimate
 d primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07733050
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776639-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:S-1: Phase 2 readout est. (NCT07776639)
DESCRIPTION:S-1\, phase 2.\nStudy: Iparomlimab and Tuvonralimab Injection (
 QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Aden
 ocarcinoma of the Stomach and Gastroesophageal Junction\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07776639
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06038461-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:S-1: Phase 1/2 readout est. (NCT06038461)
DESCRIPTION:S-1\, phase 1/2.\nStudy: An Open\, Single-center Clinical Study
  of Surufatinib Combined With Temozolomide and S-1 in the First-line Treat
 ment of Advanced Neuroendocrine Tumors\nEstimated primary completion: 15 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060384
 61
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892573-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:S-1: Phase na readout est. (NCT07892573)
DESCRIPTION:S-1\, phase na.\nStudy: Becotatug Vedotin Plus Anti-PD-1 and S-
 1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Faile
 d at Least One Line of Standard Therapy\nEstimated primary completion: 30 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07892
 573
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923396-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 1 readout est. (NCT07923396)
DESCRIPTION:S-1\, phase 1\, Gastric Cancer.\nStudy: GK01 Cell Therapy in Ga
 stric Cancer With Peritoneal Metastasis\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07923396
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018063-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:S-1: Phase 2 readout est. (NCT07018063)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Neoadjuvant Nab-Paclita
 xel Plus Oxaliplatin\, S-1\, and Sintilimab in Early-Onset Resectable Gast
 ric Cancer\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07018063
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229496-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 1 readout est. (NCT06229496)
DESCRIPTION:S-1\, phase 1.\nStudy: Dose Escalation and Dose Expansion Study
  of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06229496
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732856-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 1/2 readout est. (NCT06732856)
DESCRIPTION:S-1\, phase 1/2\, Gastric Cancer.\nStudy: A Phase Ib/II Trial o
 f Neoadjuvant Zolbetuximab Plus Docetaxel\, Oxaliplatin and S-1 Chemothera
 py in Patients With Locally Advanced Gastric Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06732856
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 2 readout est. (NCT04566380)
DESCRIPTION:S-1\, phase 2.\nStudy: ONO-4538 Phase II Rollover Study (ONO-45
 38-98)\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374250-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 2 readout est. (NCT07374250)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Perioperative Ivonescim
 ab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Aden
 ocarcinoma\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07374250
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06766578-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:S-1: Phase 2 readout est. (NCT06766578)
DESCRIPTION:S-1\, phase 2.\nStudy: Clinical Study of Low-dose Interval Radi
 otherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therap
 y for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06766578
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571461-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:S-1: Phase 3 readout est. (NCT06571461)
DESCRIPTION:S-1\, phase 3.\nStudy: Liposomal Irinotecan in Combination With
  Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Post
 operative Adjuvant Therapy for Pancreatic Cancer\nEstimated primary comple
 tion: January 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 -1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6571461
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561775-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:S-1: Phase 2 readout est. (NCT07561775)
DESCRIPTION:S-1\, phase 2.\nStudy: Adebrelimab Plus S-1 for Resected Cholan
 giocarcinoma\nEstimated primary completion: 1 January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07561775
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847710-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:S-1: Phase 2 readout est. (NCT07847710)
DESCRIPTION:S-1\, phase 2.\nStudy: Perioperative Retlirafusp Alfa(Anti-PD-L
 1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepat
 ic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholan
 giocarcinoma: A Multicenter\, Single-Arm\, Exploratory Phase II Trial\nEst
 imated primary completion: 1 March 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07847710
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:S-1: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:S-1\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Allogenei
 c NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced
  Solid Tumors\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515625-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:S-1: Phase 2 readout est. (NCT07515625)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Efficacy of Sintilimab 
 Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-posi
 tive Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated primary c
 ompletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07515625
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07556640-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:S-1: Phase 2 readout est. (NCT07556640)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: LM-302 and S-1 Plus Int
 raperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-posit
 ive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Me
 tastasis: a Prospective\, Exploratory Study\nEstimated primary completion:
  30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07556
 640
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569068-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:S-1: Phase 2 readout est. (NCT07569068)
DESCRIPTION:S-1\, phase 2.\nStudy: Neoadjuvant Tislelizumab + LM-302 + S-1 
 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07569068
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621484-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:S-1: Phase 2 readout est. (NCT07621484)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: HIPEC Priming Followed 
 by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer\nEstimate
 d primary completion: 9 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07621484
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464756-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:S-1: Phase 2 readout est. (NCT07464756)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: SHR-1701 With or Withou
 t Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gas
 tric Cancer\nEstimated primary completion: 31 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07464756
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:S-1: Phase 2 readout est. (NCT07685704)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Combined Wi
 th Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3
 + or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma:
  a Phase II Open-Label Study\nEstimated primary completion: June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07685704
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243938-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:S-1: Phase 2 readout est. (NCT07243938)
DESCRIPTION:S-1\, phase 2\, Colorectal Cancer.\nStudy: Phase II Basket Tria
 l: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BA
 SKET)\nEstimated primary completion: 30 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07243938
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944664-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:S-1: Phase 4 readout est. (NCT07944664)
DESCRIPTION:S-1\, phase 4\, Gastric Cancer.\nStudy: A Phase 4\, Single-arm\
 , Interventional Study to Evaluate the Safety and Tolerability of Zolbetux
 imab Plus SOX as First-line Treatment of Chinese Participants With HER2-ne
 gative\, Claudin (CLDN)18.2-Positive\, La Unresectable or Metastatic GC/GE
 JC\nEstimated primary completion: August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07944664
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194005-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:S-1: Phase 2 readout est. (NCT07194005)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Conversion Therapy With
  RC48\, Sintilimab\, and SOX for HER2 1+/2+ Unresectable Gastric Cancer\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07194005
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893392-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:S-1: Phase 2 readout est. (NCT07893392)
DESCRIPTION:S-1\, phase 2.\nStudy: Phase II Study of Primary Tumor Resectio
 n and Selective Lymph Node Dissection Followed by RT for BTC With Lymph No
 de Metastases\nEstimated primary completion: 8 October 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07893392
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366528-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:S-1: Phase 3 readout est. (NCT07366528)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Adjuvant Oxaliplatin Pl
 us S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer\nEstimated p
 rimary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07366528
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699939-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:S-1: Phase 2 readout est. (NCT07699939)
DESCRIPTION:S-1\, phase 2.\nStudy: Perioperative HLX10 (Serplulimab) With S
 -1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Eso
 phagogastric Junction Adenocarcinoma\nEstimated primary completion: 30 Nov
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07699939
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384234-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:S-1: Phase 2 readout est. (NCT07384234)
DESCRIPTION:S-1\, phase 2.\nStudy: SHR-1701 Combined With Chemotherapy for 
 Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metast
 asis\nEstimated primary completion: 30 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07384234
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492615-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290220
DTEND;VALUE=DATE:20290221
SUMMARY:S-1: Phase 2 readout est. (NCT07492615)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: A Clinical Study of Sin
 tilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy 
 for Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated primary co
 mpletion: 20 February 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07492615
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636824-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:S-1: Phase 2 readout est. (NCT07636824)
DESCRIPTION:S-1\, phase 2.\nStudy: Efficacy and Safety of Postoperative Con
 current Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallblad
 der Carcinoma: A Multicenter Prospective Phase II Study\nEstimated primary
  completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07636824
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007182-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:S-1: Phase 2 readout est. (NCT07007182)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Conversion Therapy Plus
  Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric 
 Cancer\nEstimated primary completion: 1 April 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07007182
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745790-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:S-1: Phase 2 readout est. (NCT07745790)
DESCRIPTION:S-1\, phase 2.\nStudy: Safety and Efficacy of Multimodal Therma
 l Therapy (MTT) Combined With KRAS G12V mRNA Vaccine\, S-1\, and Sintilima
 b in Patients With Metastatic Pancreatic Cancer\nEstimated primary complet
 ion: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-
 1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 745790
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:S-1: Phase 2 readout est. (NCT06881017)
DESCRIPTION:S-1\, phase 2\, Gastric Cancer.\nStudy: Establishment of Precis
 ion Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel
  Molecular Subtyping\nEstimated primary completion: 1 August 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828873-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:S-1: Phase 2 readout est. (NCT07828873)
DESCRIPTION:S-1\, phase 2.\nStudy: A Single-Arm Study of QL1706 Combined Wi
 th DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcin
 oma\nEstimated primary completion: September 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07828873
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662877-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:S-1: Phase 2/3 readout est. (NCT06662877)
DESCRIPTION:S-1\, phase 2/3.\nStudy: Anlotinib Plus Nab-Paclitaxels and S-1
  for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment\
 nEstimated primary completion: 1 September 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06662877
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522151-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:S-1: Phase 3 readout est. (NCT07522151)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Clinical Study of Adebr
 elimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroe
 sophageal Junction Cancer\nEstimated primary completion: December 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07522151
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483567-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:S-1: Phase 2 readout est. (NCT07483567)
DESCRIPTION:S-1\, phase 2.\nStudy: IBI343 in Combination With Sintilimab an
 d SOX Regimen for Perioperative Treatment of Resectable\, Locally Advanced
  Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary co
 mpletion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07483567
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903273-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:S-1: Phase 2 readout est. (NCT06903273)
DESCRIPTION:S-1\, phase 2.\nStudy: Neoadjuvant Tislelizumab\, Gemcitabine\,
  Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma\nEstimated 
 primary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/s-1#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06903273
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02487992-2242@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20430731
DTEND;VALUE=DATE:20430801
SUMMARY:S-1: Phase 2 readout est. (NCT02487992)
DESCRIPTION:S-1\, phase 2\, Colorectal Cancer.\nStudy: The Study of CIK Plu
 s S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced 
 Colorectal Cancer\nEstimated primary completion: July 2043. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT02487992
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
